Company:  BLUEBIRD BIO, INC. (BLUE)
Form Type:  4
Filing Date:  8/10/2018 
CIK:  0001293971 
Address:  60 BINNEY STREET 
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  339-499-9300 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$125.34  
Change: 
2.56 (2.09%)  
Trade Time: 
Nov 16  
Market Cap: 
$6.86B
Trade BLUE now with 

© 2018  
Description of Business
We are a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer. With our lentiviral-based gene therapy and gene editing capabilities, we have built an integrated product platform with broad therapeutic potential in a variety of indications. We believe that gene therapy for severe genetic diseases has the potential to change the way these patients are treated by correcting the underlying genetic defect that is the cause of their disease, rather than offering treatments that only address their symptoms. Our clinical programs in severe genetic diseases include our LentiGlobin® product candidate as a treatment for transfusion-dependent ?-thalassemia, or TDT, and severe sickle cell disease, or severe SCD, and our Lenti-D(TM) product candidate as a treatment for cerebral adrenoleukodystrophy, or CALD, a rare hereditary neurological disorder.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES